MD-22-1001-1

MD-22-1001-1 is an injectable antibacterial drug candidate currently under development by Meiji for the treatment of bacterial infections in cattle. Positioned within Meiji's veterinary pharmaceutical pipeline, the asset is designed for parenteral administration to manage infectious diseases in livestock. While specific details regarding its chemical structure, molecular target, and precise mechanism of action have not been publicly disclosed, it is categorized as an antibacterial agent in preclinical development. The drug aims to address the therapeutic needs of bovine health by providing a systemic treatment option for bacterial pathogens.